|
|
 |
|
Viewing report
|
|
|
|
Overcoming Challenges in Antibacterial Drug Discovery and Development
Decision Resources, Inc., March 2007, Pages: 39
The antibacterial market is highly mature, yet there is a compelling need to discover new antibacterials to combat the escalating threats of drug resistance, the threats posed by new and re-emerging pathogens, and bioterrorism threats. In recent years, unmet medical needs and the advent of genomics technologies renewed companies’ interest concerning antibacterial drug discovery. Smaller pharmaceutical companies and biotech companies have filled the void created when big pharma abandoned the arena and are now developing more than 80% of today’s emerging antibacterial agents.
Get the Answers You Need to Shape Your Strategy
- Some approaches to antibacterial drug development are more notable advances than others. What approaches are these and which approaches should produce drugs that command higher prices than conventional antibiotics?
- Several factors are driving today’s antibacterial drug discovery efforts. What factors are most relevant to fighting pathogens in community settings? What factors are most relevant to fighting pathogens in hospital settings?
- Although big pharma has largely abandoned the development of antibacterial agents, it has maintained a stake in the antibacterial market through a variety of marketing and sales alliances. Which current partnerships between big pharma and smaller pharmaceutical companies show the greatest promise?
- Several antibacterial blockbusters were on the market in 2005, yet most pharmaceutical companies had a sparse antibacterial drug portfolio. Which company is an exception to the rule that the antibacterial drug portfolio of big pharma companies typically is dominated by a blockbuster agent? What lessons can be learned from this company’s strategy of developing several moderately successful drugs?
- Despite financial and regulatory hurdles impeding the development of antibacterial agents, commercial opportunities to develop antibacterials that are effective against drug-resistant pathogens, especially in hospital settings, still remain. What are these opportunities? What incentives would bring more players into antibacterial drug discovery and development?
Scope
- New approaches to discovering antibacterial agents: the relative importance of genomics, novel antibodies, topical antibacterial agents, PDF inhibitors, novel beta-lactams, peptides and peptide mimetics, fatty acid biosynthesis inhibitors, and combination therapies.
- Business strategies: drug discovery, marketing and sales alliances, big pharma’s out-licensing programs, mergers and acquisitions, and strategies for niche markets.
- Company profiles: Oscient Pharmaceuticals, Cubist Pharmaceuticals, Replidyne, Novexel.
- Outlook: commercial opportunity and diagnostic, regulatory, financial, and legislative incentives.
- Spectrum expert commentary: an award-winning researcher explains how quorum sensing may shine light on a new path to novel antibacterial drug development.
Customers who bought this item also bought
Antiparasitic and Antibacterial Drug Discovery: From Molecular Targets to Drug Candidates
Antibacterial Drug Resistance: Expanding Opportunities in the Hospital Market
Licensing in Antibacterial R&D - Filling the Gaps
Antibacterial Drug Licensing Opportunities: Analysis, Rating, and Ranking - A Worldwide Study
Antibiotics and Drug Resistance
Genomics in Drug Discovery and Development
Antibacterial: Drug Licensing Opportunities, 2002
Antibacterial Market Survey: Analyses and Forecasts…Technology, Sales and Company Profiles
Stakeholder Opinions: Skin Infections - Where In The Antibacterial Lifecycle?
Cancer Drug Resistance
Stakeholder Insight: The Hospital Antibacterial Market - Specialist Products Drive Market Growth
Strategic Perspectives: The Hospital Antibacterial Market - Defining a Sector Specific Strategy
|
|
|
|
